Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Pliant Therapeutics, Inc.
National Cancer Institute (NCI)
Hoffmann-La Roche
Arvinas Inc.
Jonsson Comprehensive Cancer Center
University of Pittsburgh
West China Hospital
Actym Therapeutics, Inc.
Toray Industries, Inc
Eli Lilly and Company
SOLTI Breast Cancer Research Group
ABM Therapeutics Shanghai Company Limited
Rain Oncology Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
University of California, San Diego
ABM Therapeutics Corporation
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
NextCure, Inc.
University of Florida
Hoffmann-La Roche
Klus Pharma Inc.
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
AbbVie
AbbVie
Fore Biotherapeutics
University of California, San Francisco
FeRx